These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 30334956)

  • 1. Comparison of the response of frequently relapsing steroid-dependent minimal change nephrotic syndrome to rituximab therapy between childhood-onset and adult-onset disease.
    Iwabuchi Y; Miyabe Y; Makabe S; Nakano M; Manabe S; Karasawa K; Moriyama T; Nitta K
    Medicine (Baltimore); 2018 Oct; 97(42):e12704. PubMed ID: 30334956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic efficacy of rituximab for the management of adult-onset steroid-dependent nephrotic syndrome: a retrospective study.
    Katsuno T; Masuda T; Saito S; Kato N; Ishimoto T; Kato S; Kosugi T; Tsuboi N; Kitamura H; Tsuzuki T; Ito Y; Maruyama S
    Clin Exp Nephrol; 2019 Feb; 23(2):207-214. PubMed ID: 30121802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab as a Therapeutic Option for Steroid-Sensitive Minimal Change Nephrotic Syndrome in Adults.
    Iwabuchi Y; Moriyama T; Itabashi M; Takei T; Nitta K
    Contrib Nephrol; 2018; 195():12-19. PubMed ID: 29734146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amelioration of the adverse effects of prednisolone by rituximab treatment in adults with steroid-dependent minimal-change nephrotic syndrome.
    Miyabe Y; Takei T; Iwabuchi Y; Moriyama T; Nitta K
    Clin Exp Nephrol; 2016 Feb; 20(1):103-10. PubMed ID: 26138356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term outcome of childhood-onset complicated nephrotic syndrome after a multicenter, double-blind, randomized, placebo-controlled trial of rituximab.
    Kamei K; Ishikura K; Sako M; Aya K; Tanaka R; Nozu K; Kaito H; Nakanishi K; Ohtomo Y; Miura K; Takahashi S; Morimoto T; Kubota W; Ito S; Nakamura H; Iijima K;
    Pediatr Nephrol; 2017 Nov; 32(11):2071-2078. PubMed ID: 28664242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term prognosis of adult patients with steroid-dependent minimal change nephrotic syndrome following rituximab treatment.
    Iwabuchi Y; Takei T; Moriyama T; Itabashi M; Nitta K
    Medicine (Baltimore); 2014 Dec; 93(29):e300. PubMed ID: 25546674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of single-dose rituximab on steroid-dependent minimal-change nephrotic syndrome in adults.
    Takei T; Itabashi M; Moriyama T; Kojima C; Shiohira S; Shimizu A; Tsuruta Y; Ochi A; Amemiya N; Mochizuki T; Uchida K; Tsuchiya K; Nitta K
    Nephrol Dial Transplant; 2013 May; 28(5):1225-32. PubMed ID: 23239834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of Rituximab for Minimal Change Disease and Focal Segmental Glomerulosclerosis with Frequently Relapsing or Steroid-Dependent Nephrotic Syndrome in Adults: A Chinese Multicenter Retrospective Study.
    Lan L; Lin Y; Yu B; Wang Y; Pan H; Wang H; Lou X; Lang X; Zhang Q; Jin L; Yang Y; Xiao L; Chen J; Han F
    Am J Nephrol; 2024; 55(1):25-36. PubMed ID: 37963441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrospective single-arm cohort study of steroid-dependent minimal change nephrotic syndrome treated with very low-dose rituximab.
    Fujimoto K; Kagaya Y; Kumano S; Fujii A; Tsuruyama Y; Matsuura T; Yamazaki K; Nomura K; Okada K; Okino K; Adachi H; Furuichi K; Yokoyama H
    Clin Nephrol; 2021 Jan; 95(1):29-36. PubMed ID: 33074094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab for minimal-change nephrotic syndrome in adulthood: predictive factors for response, long-term outcomes and tolerance.
    Guitard J; Hebral AL; Fakhouri F; Joly D; Daugas E; Rivalan J; Guigonis V; Ducret F; Presne C; Pirson Y; Hourmant M; Glachant JC; Vendrely B; Moranne O; Faguer S; Chauveau D
    Nephrol Dial Transplant; 2014 Nov; 29(11):2084-91. PubMed ID: 24920841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Age of Onset and Disease Course in Biopsy-Proven Minimal Change Disease: An Analysis From the Cure Glomerulonephropathy Network.
    Chen DP; Helmuth ME; Smith AR; Canetta PA; Ayoub I; Mucha K; Kallash M; Kopp JB; Gbadegesin R; Gillespie BW; Greenbaum LA; Parekh RS; Hunley TE; Sperati CJ; Selewski DT; Kidd J; Chishti A; Reidy K; Mottl AK; Gipson DS; Srivastava T; Twombley KE;
    Am J Kidney Dis; 2023 Jun; 81(6):695-706.e1. PubMed ID: 36608921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of remission following a single dose of rituximab alone in a patient with minimal change nephrotic syndrome.
    Amemiya N; Takei T; Kojima C; Nokiba H; Itabashi M; Nitta K
    Clin Exp Nephrol; 2011 Dec; 15(6):933-6. PubMed ID: 21823044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined cyclosporine and prednisolone therapy using cyclosporine blood concentration monitoring for adult patients with new-onset minimal change nephrotic syndrome: a single-center pilot randomized trial.
    Shirai S; Imai N; Sueki S; Matsui K; Tominaga N; Sakurada T; Yasuda T; Kimura K; Shibagaki Y
    Clin Exp Nephrol; 2018 Apr; 22(2):283-290. PubMed ID: 28699032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful therapeutic use of a single-dose of rituximab on relapse in adults with minimal change nephrotic syndrome.
    Sawara Y; Itabashi M; Kojima C; Tabata H; Kamei D; Kawanishi K; Moriyama T; Sugiura H; Tsukada M; Takei T; Ogawa T; Yoshida T; Arai J; Uchida K; Tsuchiya K; Nitta K
    Clin Nephrol; 2009 Jul; 72(1):69-72. PubMed ID: 19640390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Term Efficacy and Safety of Repeated Rituximab to Maintain Remission in Idiopathic Childhood Nephrotic Syndrome: An International Study.
    Chan EY; Yu ELM; Angeletti A; Arslan Z; Basu B; Boyer O; Chan CY; Colucci M; Dorval G; Dossier C; Drovandi S; Ghiggeri GM; Gipson DS; Hamada R; Hogan J; Ishikura K; Kamei K; Kemper MJ; Ma AL; Parekh RS; Radhakrishnan S; Saini P; Shen Q; Sinha R; Subun C; Teo S; Vivarelli M; Webb H; Xu H; Yap HK; Tullus K
    J Am Soc Nephrol; 2022 Jun; 33(6):1193-1207. PubMed ID: 35354600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab and minimal change nephrotic syndrome: a therapeutic option.
    Takei T; Nitta K
    Clin Exp Nephrol; 2011 Oct; 15(5):641-647. PubMed ID: 21611755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of repeat-dose rituximab maintenance therapy for minimal change disease in adults.
    Taguchi S; Ohtake T; Mochida Y; Ishioka K; Moriya H; Hidaka S; Kobayashi S
    Clin Exp Nephrol; 2020 Dec; 24(12):1132-1139. PubMed ID: 32761467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcome of Japanese children with complicated minimal change nephrotic syndrome treated with mycophenolate mofetil after cyclosporine.
    Fujinaga S; Hirano D; Nishino T; Umeda C; Watanabe Y; Nakagawa M
    Pediatr Nephrol; 2019 Nov; 34(11):2417-2421. PubMed ID: 31435725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NEPHRUTIX: A randomized, double-blind, placebo vs Rituximab-controlled trial assessing T-cell subset changes in Minimal Change Nephrotic Syndrome.
    Boumediene A; Vachin P; Sendeyo K; Oniszczuk J; Zhang SY; Henique C; Pawlak A; Audard V; Ollero M; Guigonis V; Sahali D
    J Autoimmun; 2018 Mar; 88():91-102. PubMed ID: 29056249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial.
    Iijima K; Sako M; Nozu K; Mori R; Tuchida N; Kamei K; Miura K; Aya K; Nakanishi K; Ohtomo Y; Takahashi S; Tanaka R; Kaito H; Nakamura H; Ishikura K; Ito S; Ohashi Y;
    Lancet; 2014 Oct; 384(9950):1273-81. PubMed ID: 24965823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.